Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy
Henri Roché(Inserm), Hervé Curé(Institut Claudius Regaud), Louise Yelle(Institut Claudius Regaud), Francesco Cognetti(Apple (Israel)), Rana Ezzeddine(Institut Claudius Regaud), Linda T. Vahdat(Dartmouth–Hitchcock Medical Center), David Lebwohl(Intellia Therapeutics (United States)), Pierre Kerbrat(Aarhus University Hospital), Joseph A. Sparano(Tisch Cancer Institute), Craig A. Bunnell(Cornell University), L. Mauriac(Institut Bergonié), Ronald Peck(Cornell University), Jean‐Pierre Delord
Cited by 225
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
|Nature|2015|1.8k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Connecting copper and cancer: from transition metal signalling to metalloplasia
|Nature reviews. Cancer|2021|1.3k